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Summary This contribution summarizes the past and present status of ultrasound-facilitated
thrombolysis (sonolysis) with and without the use of microspheres. Different ultrasound tech-
niques are addressed and advantages as well as pitfalls are discussed.
© 2012 Elsevier GmbH.
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Intravenous thrombolysis with rt-PA is the only approved
therapy for treating acute ischemic stroke and needs to
be administered within the ﬁrst 4.5 h after symptom onset
[1]. Among other factors, the speed and completeness of
recanalization, and successive reperfusion of ischemic brain
tissue is associated with ﬁnal infarct size, restoration of
function, and ﬁnally clinical outcome. With i.v. rt-PA only,
there is a rather low percentage of patients achieving early
(30—40%) and complete (18%) recanalization [2]. Therefore,
various ways to improve speed and completeness of recanal-
ization have been studied, among others the therapeutic
use of ultrasound, alone or in combination with thrombolyt-
ics. The following brief overview reﬂects the current clinical
status of sonothrombolysis. For an extensive recent review
(and the basis for this chapter) including the experimental
background of sonothrombolysis the reader is referred to
Amaral-Silva et al. [3].Delivery of tPA to the thrombus is dependent on the resid-
ual ﬂow to and around the arterial obstruction, and better
residual ﬂow signals detected by Transcranial Doppler (TCD)
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Open access under CC BY-NC-ND license.re associated with higher recanalization rates and conse-
uently better clinical courser in stroke patients treated
ith i.v. tPA [3,4]. Proximal arterial occlusions are a marker
f clot burden and poorer response to thrombolysis in terms
f recanalization [5,6]. Therefore, proximal intracranial
cclusion is a target for more advanced reperfusion strate-
ies, among them ultrasound-enhanced thrombolysis. While
everal ultrasound techniques have been applied, the focus
f this contribution shall remain on the techniques that are
lso used in standard diagnostic ultrasound, i.e. transcranial
olor coded duplex (TCCD) and TCD.
TCD is a non-invasive technique that uses ultrasound to
ccess regional blood ﬂow by determining ﬂow velocities of
ntracranial arteries. TCD is a fast and reliable method of
btaining real-time information on the presence and loca-
ion of arterial occlusion and recanalization during or shortly
fter thrombolysis [3]. The patterns of intracranial arterial
cclusion and recanalization on TCD have been validated
gainst angiography with high sensitivity and speciﬁcity val-
es resulting in the now widely used derived thrombolysis
n brain ischemia (TIBI) grading system [7].
linical studiesigh frequencies lead to greater attenuation of ultrasound,
ower frequencies may be harmful due to tissue heating.
here are only very limited data on the effect of ultrasound
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lone (without thrombolytic drugs) to facilitate clot lysis in
cute stroke.
The TRUMBI study, a phase II clinical trial testing
he use of low frequency ultrasound insonation in acute
troke patients treated with i.v. t-PA, showed a signiﬁcant
ncrease in hemorrhage, both symptomatic and asymp-
omatic [8]. The trial included i.v. rt-PA patients within
h of symptom onset but was closed early because of
igns of ICH in 13/14 patients compared with 5/12 patients
n rt-PA only albeit identical recanalization rates. Since
hen, clinical trials restricted the use of ultrasound for
herapeutical purposes to the settings usually used for
iagnostic purposes (1—2MHz), which have proved their
afety and efﬁcacy in several experimental and clinical tri-
ls.
Alexandrov et al. reported one of the ﬁrst clinical reports
n the use of sonothrombolysis in acute stroke patients [9]
nd showed with 2MHz TCD a higher response rate to i.v.
-PA at 24 h than previously documented (40% of patients
ersus 27% in the NINDS trial showed a >10 points improve-
ent in NIHSSS or complete recovery). This pilot trial was
ollowed by a phase II randomized controlled trial CLOTBUST
Combined Lysis of Thrombus in Brain Ischemia using Tran-
cranial Ultrasound and Systemic TPA), which demonstrated
hat enhancement of the thrombolytic activity of tPA could
e safely achieved by using higher frequency (2MHz) and
ow intensity (<700mW/cm2) single element pulsed-wave
ltrasound [2]. In 126 patients randomized in a 1:1 fashion
cute rt-PA treated stroke patients were either insonated
ithin a 3-h time window for 2 h or not. rt-PA induced
rterial recanalization was increased by ultrasound (sus-
ained complete recanalization rates at 2 h: 38% versus 13%,
= 0.002) with a non-signiﬁcant trend toward an increased
ate of clinical recovery from stroke, as compared with
lacebo and at no increased cost of bleeding complica-
ions (4.8% in both arms). A phase III trial has been planned
or quite some time and protocols have been published
10]. The problem, however, is still the lack of an inves-
igator independent device, although this may be solved in
he close future (Andrei Alexandrov, personal communica-
ion).
Transcranial color coded duplex ultrasound (TCCD) has
een used in four smaller trials of ultrasound enhanced
hrombolysis [3]. In general, the results were somewhat bet-
er than control rt-PA patients with regard to recanalization
nd trends for outcome, but again at the cost of higher
leeding rates fortunately not in the same range as in the
RUMBI trial.
icrobubble-enhanced sonothrombolysis
icrobubbles (MBs, microspheres), originally developed as
ltrasound contrast agents, have been utilized for increasing
ltrasound performance in neurovascular imaging and sonol-
sis by enhanced cavitation and microstreaming [11,12].
erived from experimental studies in the 90s [13], the
pproach was consecutively applied to the clinical setting
12,14]. In a ﬁrst study Molina and colleagues used levovist®
iven at 3 time points in 38 patients compared to 73 patients
reated with either 2MHz TCD and rt-PA or rt-PA alone
12]. Complete recanalization rate 2 h after t-PA bolus was
G
g
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igniﬁcantly higher in the tPA/US/MB group (54.5%)
ompared with tPA/US (40.8%) and tPA (23.9%) groups
p = 0.038). No systemic symptoms deriving from MBs use
ere documented. Symptomatic ICH rates did not differ. A
rench TCCD (plus rt-PA plus MB versus rt-PA alone) study was
erminated prematurely because of safety concerns [15].
ther MBs have been tested but none have emerged so far
s superior to others.
Newer submicron lipid coated perﬂutren MBs
‘‘nanobubbles’’) were tested in a pilot trial and a
hase IIa study [14,16]. Preliminary data compared to
istoric controls from the CLOTBUST trial showed a higher
ate of complete recanalization (50% versus 18%, p = 0.028)
nd sustained complete recanalization at 2 h (42% versus
3%, p = 0.003). Interestingly, in a majority of patients
Bs were detected in areas with no pretreatment ﬂow,
ndicating permeation beyond intracranial occlusions [17].
he phase IIa TUCSON study [14] aimed to determine
he safety, tolerability, and activity of perﬂutren-lipid
Bs MRX-801 plus TCD insonation in sonothrombolysis.
hirty-ﬁve patients with pretreatment proximal intracra-
ial occlusions on TCD were randomized (2:1 ratio) to
ncreasing doses of MRx-801 MBs infusion over 90min.
he study was terminated prematurely by the sponsor
ecause of bleeding events in the 2nd dose tier, although
ll the 3 bleedings could have been attributed to very
evere strokes and high blood pressures during treatment.
espite that, a trend toward higher sustained complete
ecanalization rates in both MBs dose tiers compared
o control was observed (67% for Cohort 1, 46% for
ohort 2, and 33% for controls, p = 0.255). To date this
as the last sonothrombolysis study also using MBs, and
he concept remains to be rechallenged in the authors’
pinion.
onclusions
arly and effective reperfusion is the key for early ischemic
issue rescue and further good clinical outcomes. How-
ver, i.v. tPA alone can only accomplish this goal in less
han 50% of the patients. Ultrasound may be a tool to
nhance clot lysis, albeit the ﬁnal verdict has to be spoken.
t the current stage a phase III trial with an investiga-
or blinded 2MHz device using the settings of the original
LOTBUST study is underway, and the protocol has been
nalized. Future research should be dedicated to optimiz-
ng the technical setting of ultrasound, the development
f untargeted and targeted MBs and optimizing the feasi-
ility of this not so novel therapeutic approach to acute
troke.
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